No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
Rakovina Therapeutics Inc: MDA EN
Rakovina Therapeutics Inc: AUDITED ANNUAL FINANCIAL STATEMENTS EN
Rakovina Strengthens Board With Appointments of Yevgeniy Meshcherekov and David Kideckel
Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery